⚖️
Obesity
Weight management therapies including GLP-1 receptor agonists, dual agonists, and metabolic modulators.
Companies
0
Pipeline Drugs
297
Key People
366
Obesity Pipeline (297 drugs)
Preclinical: 48Pre-clinical: 33Phase 2: 32Phase 1: 20Approved: 16Approved/Commercial: 15Discovery: 14Commercial: 14Phase 3: 10Development: 8Phase 1-3: 5Not Applicable (Service Provider): 5Active: 5Research: 4Not Applicable (Service): 4Clinical: 4Phase 2-4: 4Phase 1/2: 3Service Platform: 3Regulatory Review: 3Discovery/Preclinical: 3Lead Optimization: 2Exploratory: 2Preclinical/Phase 1: 2IND-Enabling: 2Phase 2/3 (via licensee): 1Clinical Trials: 1Target Discovery/Preclinical: 1Hit-to-Lead: 1Pre-commercial: 1Phase 2a: 1Phase 2B: 1Phase 1b/2: 1NA (Service for all trial phases): 1Pre-commercial (UKCA/CE marked): 1Phase I-IV: 1Phase 2b/3: 1Clinical-stage (Phase not specified): 1Unknown: 1Not Specified: 1Phase 1/2a: 1Varies by Sponsor Protocol: 1Development/Commercial: 1Phase 1/1b: 1R&D: 1IDE/comparative study: 1Launched: 1Launched/Phase 3: 1Phase 3 / Approved: 1Phase 2b: 1Phase 1b: 1Marketed: 1Phase 1b/2a: 1Phase 3 (Planned): 1Pivotal: 1Optimization: 1Phase 3 Ready: 1Preclinical / Phase 1: 1Phase 2 / Planning: 1Discovery / Preclinical: 1Phase 3 Completed: 1
| Drug | Company | Indication | Phase |
|---|---|---|---|
| Oral Non-Incretin Small Molecule | Alaunos Therapeutics | Obesity / Metabolic Disorders | Preclinical |
| Undisclosed bLNP-Gene Therapy | BioGene Therapeutics | Diabetes (Type 1/2) | Preclinical |
| GLP-1 Analog Transdermal Patch | QuiaPEG Pharmaceuticals | Obesity / Weight Management | Preclinical |
| Generic Semaglutide Injection (Obeda) | Dr. Reddy's Laboratories | Type 2 Diabetes | Approved |
| Generic Semaglutide (Oral) | Dr. Reddy's Laboratories | Type 2 Diabetes, Obesity | Development |
| Bevacizumab Biosimilar | Dr. Reddy's Laboratories | Various Cancers | Approved |
| Rituximab Biosimilar | Dr. Reddy's Laboratories | Non-Hodgkin Lymphoma, Rheumatoid Arthritis | Approved |
| Lenacapavir | Dr. Reddy's Laboratories | HIV-1 Infection | Approved |
| Toripalimab | Dr. Reddy's Laboratories | Recurrent/Metastatic Nasopharyngeal Carcinoma | Approved |
| CAR T-Cell Therapy Program | Dr. Reddy's Laboratories | Relapsed/Refractory Multiple Myeloma | Development |
| Injectable Contraceptive | Dr. Reddy's Laboratories | Women's Health / Family Planning | Development |
| BioChaperone® Lispro (THDB0206) | Adocia | Type 1 Diabetes | Phase 3 |
| BioChaperone® Lispro | Adocia | Type 2 Diabetes | Phase 3 |
| BioChaperone® Combo (Insulin Glargine / Lixisenatide) | Adocia | Type 2 Diabetes | Phase 2 |
| BioChaperone® Glucagon | Adocia | Hypoglycemia | Phase 1 |
| AdOral® Insulin | Adocia | Diabetes | Preclinical |
| AdoShell® Islet Cell Therapy | Adocia | Type 1 Diabetes | Preclinical |
| AdoXLong Platform | Adocia | Diabetes & Obesity | Discovery |
| Icovamenib (BMF-219) | Biomea Fusion | Type 2 Diabetes (Insulin-Deficient) | Phase 2 |
| BMF-650 | Biomea Fusion | Obesity / Metabolic Disease | Preclinical |
| AJN003 (LuCI™) | AltrixBio | Type 2 Diabetes | Pre-clinical |
| AJN003 Platform | AltrixBio | Obesity / Weight Management | Pre-clinical |
| BIO101 (20-hydroxyecdysone) | Biophytis | Sarcopenia | Phase 3 |
| MASSIVE Project Candidates | Biophytis | Sarcopenia (Next-generation) | Discovery |
| AI Platform Candidates | Biophytis | Dry Age-Related Macular Degeneration (AMD) | Discovery |
| AlterG NEO | AlterG | Rehabilitation & Training / General Unweighting | Commercial |
| AlterG PRO | AlterG | Athletic Performance & High-Level Rehabilitation | Commercial |
| Breezing Med Commercialization | Breezing | Weight Management, Nutritional Assessment | Commercial |
| Breezing Pro Market Expansion | Breezing | Sports Science, Research, Wellness | Commercial |
| MADx ALEX2 Allergy Explorer | ALPCO Diagnostics | Allergen sensitization (IgE detection) | Approved/Commercial |
| MADx ALEX3 Allergy Explorer | ALPCO Diagnostics | Allergen sensitization (IgE detection) | Approved/Commercial |
| MADx FOX Food Xplorer | ALPCO Diagnostics | Food intolerance/tolerance (IgG detection) | Approved/Commercial |
| GeneProof CT/NG/MG Multiplex PCR Kit | ALPCO Diagnostics | Sexually Transmitted Infections (Chlamydia, Gonorrhea, Mycoplasma) | Approved/Commercial |
| GeneProof CMV PCR Kit | ALPCO Diagnostics | Cytomegalovirus infection/viral load | Approved/Commercial |
| GeneProof HPV Screening PCR Kit | ALPCO Diagnostics | Human Papilloma Virus infection | Approved/Commercial |
| GeneProof HHV-8 PCR Kit | ALPCO Diagnostics | Human Herpesvirus 8 infection | Approved/Commercial |
| myCROBE Instrument | ALPCO Diagnostics | Automated sample-to-answer PCR | Approved/Commercial |
| croBEE 2.0 System | ALPCO Diagnostics | Automated nucleic acid extraction | Approved/Commercial |
| Calprotectin Immunoturbidimetric Assay | ALPCO Diagnostics | Inflammatory Bowel Disease diagnosis & differentiation from IBS | Approved/Commercial |
| Pancreatic Elastase Chemiluminescence ELISA | ALPCO Diagnostics | Exocrine pancreatic insufficiency | Approved/Commercial |
| AutoPlex GI Biomarker Panels | ALPCO Diagnostics | Multiplex gastrointestinal disease markers | Approved/Commercial |
| KleeYa Instrument & Assays | ALPCO Diagnostics | Flexible chemiluminescence biomarker testing | Approved/Commercial |
| Insulin Chemiluminescence ELISA | ALPCO Diagnostics | Insulin measurement in human serum/plasma | Approved/Commercial |
| Direct Saliva Melatonin ELISA | ALPCO Diagnostics | Melatonin measurement in human saliva | Approved/Commercial |
| Invisicare Dermatology Platform | Skinvisible Pharmaceuticals | Various Dermatological Conditions (e.g., via licensee) | Phase 2/3 (via licensee) |
| QRX003 (via Quoin Pharmaceuticals) | Skinvisible Pharmaceuticals | Netherton Syndrome | Clinical Trials |
| Transdermal Obesity Formulations | Skinvisible Pharmaceuticals | Obesity / Glucose Control | Pre-clinical |
| Cannabinoid Delivery (with Ovation Science) | Skinvisible Pharmaceuticals | Obesity / Metabolic Health | Research |
| Obesity Target Discovery Collaboration | Fauna Bio | Obesity | Target Discovery/Preclinical |
| Project ADAPT (Space Health) | Fauna Bio | Muscle/Bone Loss in Microgravity | Research |
Key People in Obesity
HW
Holger Weis
Chair of the Board of Directors
Alaunos Therapeutics
CH
Curtis Hogue
Director
Alaunos Therapeutics
JV
Jaime Vieser
Director
Alaunos Therapeutics
DF
Dr. Francis Tavares, PhD.
Chief Technology Officer
BioGene Therapeutics
DK
Dr. Kamal Albarazanji
Senior Director of Metabolic Research
BioGene Therapeutics
RS
Raj S. Pruthi, MD, MHA, FACS
Director
BioGene Therapeutics
RG
Richard Glimstedt
Chief Executive Officer (CEO)
QuiaPEG Pharmaceuticals
EI
Erez Israeli
Chief Executive Officer
Dr. Reddy's Laboratories
DS
Deepak Sapra
CEO, API & Services
Dr. Reddy's Laboratories
MR
M.V. Ramana
CEO, Branded Markets
Dr. Reddy's Laboratories
DM
Dr. Murali Ramachandra
Chief Executive Officer, Aurigene Oncology
Dr. Reddy's Laboratories
KV
Krishna Venkatesh
Global Head of Quality and Pharmacovigilence
Dr. Reddy's Laboratories
DK
Dr. Kallam Anji Reddy
Founder
Dr. Reddy's Laboratories
OS
Olivier Soula
Chief Executive Officer, Co-founder
Adocia
MG
Mathieu-William Gilbert
Chief Financial Officer - Chief Operating Officer
Adocia